Brief: Xvivo Perfusion Q1 Adjusted EBITDA Up At SEK 6.3 Mln
April 21 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* INTERIM REPORT JANUARY-MARCH 2021
* Q1 ADJUSTED OPERATING PROFIT BEFORE DEPRECIATION AND
AMORTIZATION (EBITDA) AMOUNTED TO SEK 6.3 MILLION (5.1)
* Q1 NET SALES AMOUNTED TO SEK 58.3 MILLION (46.5)
Source text for Eikon: ID:nMFN9G0CWH
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength